Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Beijing Centers for Diseases Control and Prevention (Beijing CDC) has selected Sinovac Biotech, a China-based vaccine manufacturer, to supply its hepatitis A vaccine Healive to the Beijing Expanded Program of Immunization (EPI).
Subscribe to our email newsletter
Sinovac said that, as part of the bidding process, the Beijing CDC will evaluate potential suppliers and assigns scores for different factors, including product quality, service and price.
Based on the comprehensive score, Sinovac was selected one of the two suppliers and was allocated a greater share of the total purchase order. The total ordered quantity allocated to Sinovac is approximately 477,000 doses.
Weidong Yin, chairman, president and CEO of Sinovac, said: “We are very pleased to have been awarded the purchase order for our hepatitis A vaccine by the Beijing Government, as it is a testament to our core competencies as a high quality domestic vaccine manufacturer. We will leverage our manufacturing capacity and established quality controls to produce the doses pursuant to the purchase order.”